JCNBC's Jim Cramer's: The Go-To Medical Marijuana Stock

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, pointed to the American Academy of Neurology's recent study that paints medical marijuana in positive light.

The findings showed benefits mainly for patients with multiple sclerosis. He suggested medical marijuana has been found to help in other areas as well, including pain, epilepsy and cancer.

And although the U.S. is slowly recognizing the benefits of marijuana for medicinal purposes, investors are curious as to which stock is in the best position to take advantage.

Cramer suggests GW Pharmaceuticals as the go-to stock for investors. The company makes the cannabinoid medicine Sativex, which is marketed for the treatment of spasticity in multiple sclerosis patients.

"I really believe" in GW Pharmaceuticals, he said, adding that the U.K.-based company will have an easier time with marijuana testing since it is in England, rather than the U.S.

The stock is "still down a lot from its high," and this company will solve a lot of pain issues, Cramer concluded.

Story Source: The above story is based on materials provided by THE REGISTER CITIZEN

Note: Materials may be edited for content and length

Click here to read